Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study by Samantha Pozzi, Stefania Badiali, Alessandro Corso, Pellegrino Musto, Attilio Guarini, Carla Minoia, Donatella Vincelli, Roberto Ria, Luciano Masini, Giovanni Quarta, Massimo Gentile, Carla Mazzone, Antonio Palumbo, and Fortunato Morabito Blood Volume 122(21):3212-3212 November 15, 2013 ©2013 by American Society of Hematology
Duration of remission. Duration of remission. Kaplan-Meier estimates (in months) with 95% CI of DR in 28 patients treated with BdL for relapsed MM. Samantha Pozzi et al. Blood 2013;122:3212 ©2013 by American Society of Hematology